Early Access — free while we kick the tires
EdgarHawk

Schimmelpennink Evert B.

President, CEO and Secretary

Director Officer

Latest: President, CEO and Secretary buying · March 2026

1 filing analyzed · 1 company · Latest 2026-03-30

Companies

Company Buys Sells Direction
LENZ Therapeutics, Inc. LENZ 1 0 Net buying

Activity

March 2026
high
Buy
28,089 shares
$251,411
Significance 7/10

LENZ CEO Schimmelpennink bought 28,089 shares at $8.95; stock down 83.1% from 52-week high, cluster buy pattern detected.

Schimmelpennink, as President, CEO and Secretary, purchased 28,089 shares at $8.95 on 2026-03-27, increasing holdings from 49,200 to 77,289 shares (+57.1%). The purchase occurred in a context of severe price deterioration: the stock is trading at $8.29, down 83.1% from its 52-week high of $49.05, and has declined 38.6% in the past 30 days and 48.6% over 90 days. Critically, a cluster buy pattern is present—2 other insiders also purchased within the past 14 days—suggesting coordinated accumulation by company leadership. LENZ remains unprofitable (net income of $-16.7M on quarterly revenue of $12.5M), adding material uncertainty to whether insider purchases reflect conviction or other motives. The combination of leadership concentration, significant stock deterioration, persistent losses, and synchronized insider buying warrants investor scrutiny of both the company's near-term operational trajectory and any material information these transactions might signal.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access